1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Mitochondrial Metabolism

Mitochondrial Metabolism

Mitochondria use multiple carbon fuels to produce ATP and metabolites, including pyruvate, which is generated from glycolysis; amino acids such as glutamine; and fatty acids. These carbon fuels feed into the TCA cycle in the mitochondrial matrix to generate the reducing equivalents NADH and FADH2, which deliver their electrons to the electron transport chain. Mitochondria are complex organelles that play an important role in many facets of cellular function, from metabolism to immune regulation and cell death. Mitochondria are actively involved in a wide variety of cellular processes and molecular interactions, such as calcium buffering, lipid flux, and intracellular signaling. It is increasingly recognized that mitochondrial dysfunction is a hallmark of many diseases such as obesity/diabetes, cancer, cardiovascular and neurodegenerative diseases. Mitochondrial metabolism is a key determinant of tumor progression by impacting on functions such as epithelial-to-mesenchymal transition. Mitochondrial metabolism and derived oncometabolites shape the epigenetic landscape to alter aggressiveness features of cancer cells. Changes in mitochondrial metabolism are relevant for the survival of tumors in response to therapy.

Mitochondrial Metabolism Related Products (109):

Cat. No. Product Name Effect Purity
  • HY-100941
    CCCP
    Inhibitor 99.83%
    CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
  • HY-B1756
    Rotenone
    Inhibitor 99.65%
    Rotenone is an mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
  • HY-100410
    FCCP
    99.79%
    FCCP is an uncoupler of oxidative phosphorylation (OXPHOS) in mitochondria. FCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
  • HY-112879
    Mito-TEMPO
    98.35%
    Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.
  • HY-15475
    UK-5099
    Inhibitor 99.70%
    UK-5099 (PF-1005023) is a potent inhibitor of the mitochondrial pyruvate carrier (MPC). UK-5099 (PF-1005023) inhibits pyruvate-dependent O2 consumption with an IC50 of 50 nM.
  • HY-112177
    Myxothiazol
    Inhibitor ≥99.0%
    Myxothiazol, an antifungal antibiotic, is a mitochondrial electron transport chain complex III (bc1 complex) inhibitor. Myxothiazol inhibits the growth of many yeasts and fungi at concentrations between 0.01 and 3 μg/ml.
  • HY-145707
    BAY-179
    Inhibitor 99.84%
    BAY-179 is a potent, selective, and species cross-reactive complex I inhibitor (IC50=79 µM).
  • HY-N3383
    Ligustroside
    ≥98.0%
    Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages.
  • HY-15453
    Devimistat
    Inhibitor 99.59%
    Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
  • HY-W008719
    MPP+ iodide
    Inhibitor 99.93%
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT).
  • HY-112037
    IACS-010759
    Inhibitor 99.60%
    IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research.
  • HY-B0356
    Ciprofloxacin
    Inhibitor 99.32%
    Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-123986
    CTPI-2
    Inhibitor 99.90%
    CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.
  • HY-15206
    Glibenclamide
    99.79%
    Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. Glibenclamide can induce autophagy.
  • HY-B0486
    Lonidamine
    Inhibitor 99.45%
    Lonidamine (AF-1890), an antitumor agent, is a hexokinase, mitochondrial pyruvate carrier (Ki 2.5 μM in isolated rat liver mitochondria) and plasma membrane monocarboxylate transporters inhibitor, which also inhibits mitochondrial complex II.
  • HY-B0356A
    Ciprofloxacin monohydrochloride
    Inhibitor 99.78%
    Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
  • HY-B1334A
    Perhexiline maleate
    Inhibitor 99.26%
    Perhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively.
  • HY-P0025
    NIM811
    Inhibitor 98.82%
    NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
  • HY-100004
    Fumarate hydratase-IN-1
    Inhibitor 99.93%
    Fumarate hydratase-IN-1 (compound 2) is a cell-permeable fumarate hydratase inhibitor. Fumarate hydratase-IN-1 has antiproliferative activity against several cancer cell lines with a mean IC50 of 2.2 μM.
  • HY-110284
    BAM 15
    99.26%
    BAM 15 is a mitochondrial protonophore uncoupler. BAM 15 is an oxidative phosphorylation (OXPHOS) uncoupler.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.